Biomerica Reports Real-World Data: Nearly 60% of IBS Patients Achieved Clinically Meaningful Pain Reduction and 68% Achieved Bloating Reduction with the inFoods® IBS Therapy

Stock Information for Biomerica Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Biomerica Inc.

Biomerica Receives MHRA Registration for hp+detect(TM), Allowing Commercial Sales in Great Britain
Vietnam Approves Biomerica's EZ Detect(TM) for Nationwide Distribution
Biomerica Reports Second Quarter Fiscal 2026 Financial Results
Biomerica Announces CMS Medicare Payment Rate of $300 for Revolutionary inFoods® IBS Test
Egyptian Drug Authority Authorizes Biomerica's Complete Screening Test Portfolio
Biomerica's inFoods® IBS Product Featured in Biotherapeutics Quarterly, a Henry Schein Publication, Highlighting a New Precision Approach for Treating IBS
Biomerica Expands Contract Development and Manufacturing Services to Meet Growing Market Demand
Henry Schein and Biomerica Enter into Marketing Services Agreement for Biomerica's inFoods® IBS Test in the U.S.

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.